The Pharmalot View Ed Silverman STAT Plus: The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous
The Pharmalot View Ed Silverman STAT Plus: California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference
The Pharmalot View Ed Silverman Here’s how a loophole in a transparency law can distort medical practices
The Pharmalot View Ed Silverman STAT Plus: This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
The Pharmalot View Ed Silverman STAT Plus: At $475,000, new cancer drug raises thorny questions about drug pricing — and value
The Pharmalot View Ed Silverman STAT Plus: Drug makers deserve to be publicly shamed for thwarting competition from generics
The Pharmalot View Ed Silverman STAT Plus: The art of the deal? Why a money-back guarantee for drugs is a bad idea
The Pharmalot View Ed Silverman STAT Plus: If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon
The Pharmalot View Ed Silverman STAT Plus: It’s time to make it legal for Americans to order prescription drugs from abroad
The Pharmalot View Ed Silverman STAT Plus: US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it
The Pharmalot View Ed Silverman STAT Plus: The Trump administration could bring down drug prices. But it would take guts
The Pharmalot View Ed Silverman STAT Plus: Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life
The Pharmalot View Ed Silverman STAT Plus: How a $37,000-a-year medicine sets a good model for drug pricing
The Pharmalot View Ed Silverman STAT Plus: Here’s one drug safety rule the FDA should enact — quickly
The Pharmalot View Ed Silverman STAT Plus: Dear Mr. President: Your view of the FDA is misguided. Here’s why
The Pharmalot View Ed Silverman STAT Plus: Dear Vice President Pence: Stop peddling false hopes to dying patients
The Pharmalot View Ed Silverman STAT Plus: Pharma trade group vows to review membership criteria, but is this an empty promise?
The Pharmalot View Ed Silverman STAT Plus: Dear President Trump: Your big idea on drug pricing is half-baked
The Pharmalot View Ed Silverman STAT Plus: Drug industry ad campaign may be too late to save its reputation
The Pharmalot View Ed Silverman STAT Plus: Trump is considering a radical to lead FDA. That’s dangerous for public health
The Pharmalot View Ed Silverman Trump should be good medicine for the pharmaceutical industry. Here’s why
The Pharmalot View Ed Silverman STAT Plus: Pharma may have defeated Prop 61, but state battles over pricing will continue
The Pharmalot View Ed Silverman STAT Plus: Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?
The Pharmalot View Ed Silverman STAT Plus: Health officials should reject latest gambit by EpiPen maker to feed at the public trough
The Pharmalot View Ed Silverman Behind the grandstanding, Congress may have taken a key step to clarifying drug prices
The Pharmalot View Ed Silverman Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?
The Pharmalot View Ed Silverman The secretive system for vetting cancer drug use needs an urgent overhaul
The Pharmalot View Ed Silverman STAT Plus: Laws to shed light on drug pricing strategies probably won’t work